Wouter Verhoeven is an experienced business development and investment professional with multiple years experience in executive management. During his more than 15 year-plus career in biotech his main focus was in the antibody field, closing deals for pre-clinical and clinical assets. After starting at Berna Biotech in Switzerland he moved to Crucell in the Netherlands, joining the business development team initially being responsible for outlicensing antibody technologies. After several years he became responsible for the divestment of several in-house programs and in-licensing antibody programs for Crucell`s pipeline. During the last part of his time at Crucell Wouter was part of the senior BD team organizing the first licensing and equity deal with Johnson & Johnson in 2010 and subsequently the acquisition by J&J for over USD 2B in 2011. Thereafter he moved to Rabo Private Equity, part of the Rabobank, the second largest bank of the Netherlands. As Investment Manager he was responsible for investments in start-up companies in greentech and biotech companies. In 2014 Wouter moved to Madrid with his family to become the head of business and corporate development at Mabxience and was part of the executive committee. Mabxience is part of the Insud Pharma Group and develops and markets antibody biosimilars worldwide. In the 4 years at the company he helped it grow to double its size and closed several key licensing deals for commercialization of its lead assets as well as multiple preclinical deals. Also, he was responsible for the strategy development and for the launches of the biosimilar products in RoW. Wouter holds an MSc title from the Delft University of Technology in the Netherlands.